|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
12
|
|
pubmed:dateCreated |
2002-6-14
|
|
pubmed:abstractText |
Methotrexate (MTX) is active against lymphomas, but transport or polyglutamylation mutations confer MTX resistance. Because trimetrexate (TMTX) enters cells by passive diffusion and is not polyglutamylated, its activity in relapsed T-cell lymphoma was investigated.
|
|
pubmed:grant |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jun
|
|
pubmed:issn |
0732-183X
|
|
pubmed:author |
pubmed-author:CabanillasFF,
pubmed-author:DuvicMM,
pubmed-author:KingKK,
pubmed-author:McLaughlinPP,
pubmed-author:MedeirosL JLJ,
pubmed-author:MesinaOO,
pubmed-author:PhanAA,
pubmed-author:RassidakisG ZGZ,
pubmed-author:RomagueraJJ,
pubmed-author:SamuelsBB,
pubmed-author:SarrisA HAH
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
15
|
|
pubmed:volume |
20
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
2876-80
|
|
pubmed:dateRevised |
2007-11-14
|
|
pubmed:meshHeading |
pubmed-meshheading:12065565-Aged,
pubmed-meshheading:12065565-Aged, 80 and over,
pubmed-meshheading:12065565-Antimetabolites, Antineoplastic,
pubmed-meshheading:12065565-Drug Resistance, Neoplasm,
pubmed-meshheading:12065565-Female,
pubmed-meshheading:12065565-Humans,
pubmed-meshheading:12065565-Infusions, Intravenous,
pubmed-meshheading:12065565-Lymphoma, T-Cell, Cutaneous,
pubmed-meshheading:12065565-Male,
pubmed-meshheading:12065565-Middle Aged,
pubmed-meshheading:12065565-Neoplasm Recurrence, Local,
pubmed-meshheading:12065565-Treatment Outcome,
pubmed-meshheading:12065565-Trimetrexate
|
|
pubmed:year |
2002
|
|
pubmed:articleTitle |
Trimetrexate in relapsed T-cell lymphoma with skin involvement.
|
|
pubmed:affiliation |
Department of Lymphoma and Myeloma, University of Texas M.D. Anderson Cancer Center, Houston, TX, USA. a.sarris@hygeia.gr
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, U.S. Gov't, P.H.S.,
Clinical Trial, Phase II
|
